✦ LIBER ✦

Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti–Tumor Necrosis Factor-α Agents

✍ Scribed by Kestens, Christine; van Oijen, Martijn G.H.; Mulder, Charlotte L.J.; van Bodegraven, Ad A.; Dijkstra, Gerard; de Jong, Dirk; Ponsioen, Cyriel; van Tuyl, Bas A.C.; Siersema, Peter D.; Fidder, Herma H.; Oldenburg, Bas

Book ID: 119950760
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 476 KB
Volume: 11
Category: Article
ISSN: 1542-3565
DOI: 10.1016/j.cgh.2013.01.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Guillain–Barrè syndrome after treatment

Guillain–Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn's disease patient: Case report and literature review

✍ Monica Cesarini; Erika Angelucci; Tiziana Foglietta; Piero Vernia 📂 Article 📅 2011 🏛 Oxford University Press 🌐 English ⚖ 175 KB

Analysis of linkage between lymphotoxin

Analysis of linkage between lymphotoxin α haplotype and polymorphisms in 5′-flanking region of tumor necrosis factor α gene associated with efficacy of infliximab for Crohn's disease patients

✍ Takeshi Ozeki; Yoko Furuya; Chieko Nagano; Chika Matsui; Risa Takayanagi; Haruko 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 130 KB

The effect of monoclonal anti-tumor necr

The effect of monoclonal anti-tumor necrosis factor-antibody cA2 on coagulation- and fibrinolytic parameters in patients with active Crohn's disease: D.W. Hommes, H.M. van Dullemen, J. Meenan, A. van den Ende, J. Woody, G.N.J. Tytgat, S.J.H. van Deventer. Center for Thrombosis, Hemostasis, Atherosclerosis and Inflammation Research, Dept. of Gastroenterology, University of Amsterdam, Amsterdam, the Netherlands

📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 177 KB